Martin-Merino E, et al. - Researchers sought to compare the risk of venous thromboembolism (VTE) among incident users of different anti-osteoporosis medication (AOM) compared to alendronate (first line therapy). Findings revealed that across different AOM users, AO therapy-associated VTE risk did not differ. Notably, an increased risk of VTE associated with strontium ranelate use in the community was not supported in this study.